Oxford Pharmascience Group Plc

Oxford Pharmascience is a drug development company that re-develops approved drugs using proprietary formulation technologies to make them better, safer and easier to take.

The Company’s pipeline is focused on pain relief and cardiovascular disease indications addressing unmet patient needs with significant commercial potential in global markets. The company is in early stage partnering discussions for its OXPzero™ Ibuprofen and OXPzero™ Naproxen assets, superior forms of ibuprofen and naproxen which are the dominant NSAID molecules in the pain relief and anti-inflammatory sector.

Oxford Pharmascience focuses on previously approved drugs, reducing risk and resulting in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.

Oxford Pharmascience (LON:OXP) was established by a team of entrepreneurs in 2008 and is a publicly listed company on London’s Alternative Investment Market (AIM), with a strong blue chip investor base.